Cognition Therapeutics' Phase 2 MAGNIFY trial of zervimesine demonstrates slower lesion growth in geographic atrophy patients compared to placebo after 6 months of treatment.
Cognition Therapeutics' Phase 2 SHINE study demonstrates that Alzheimer's patients with lower p-tau217 levels showed 95% improvement on ADAS-Cog 11 and 108% better MMSE scores with zervimesine treatment versus placebo.
Cognition Therapeutics has published a new chemical manufacturing process for zervimesine (CT1812), featuring improved room temperature stability and enhanced production efficiency through innovative technologies.